Skip to main content
Premium Trial:

Request an Annual Quote

Myers to Leave Stanford Genome Center for HudsonAlpha; Watkins Takes Helm of Maryland Life Science Board; Lindenbergh to Chair Agendia Supervisory Board; and Others

NEW YORK (GenomeWeb News) – Richard Myers, chair of genetics at the Stanford University School of Medicine and director of the Stanford Human Genome Center, will be leaving Stanford next year to serve as scientific director of the HudsonAlpha Institute for Biotechnology in Huntsville, Ala., Alabama Governor Bob Riley said this week.
 
Myers, an Alabama native, will move slowly from a consulting role over the coming year before he takes on the full-time position next fall. Meantime, he will continue his work running the Stanford HGC and as a professor at the university.
 

Maryland Governor Martin O’Malley has tapped Human Genome Sciences’ CEO Thomas Watkins to chair the state’s Life Sciences Advisory Board. The state has also selected more than a dozen other individuals from the life sciences, technology, real estate, regulatory, and academic spheres to serve on the board.
 
Among the other members are Janet Woodcock, deputy commissioner and chief medical officer of the US Food and Drug Administration; and David Ramsay, president of the University of Maryland, Baltimore.
 

Agendia has named Hessel Lindenbergh chairman of its supervisory board. Lindebergh is chairman of NIB Capital’s supervisory board and is a board member at Royal Numico, Petroplus International, Gamma Holding,and the University of Amsterdam
 

The Pittsburgh Life Sciences Greenhouse has elected several new members to its board of directors. Electees include Peter DeComo, chairman and CEO of Renal Solutions; John Kuzmishin, VP of strategic business initiativesat the University of Pittsburgh Medical Center; John Miclot, president and CEO of Respironics; and Elizabeth Woo, VP of biotechnology for Thermo Fisher Scientific.
 

French firm Genfit has named Jean-Louis Junien as executive scientific advisor and Kia Motesharei as vice president of business.
 
Junien formerly served as CSO of Fournier Pharma – Solvay Group, CSO and research director of Ferring Pharmaceuticals, and vice president of R&D at Jouveinal-Warner-Lambert.
 
Motesharei was founder of BTeK Consulting, VP of corporate development at ActivX Biosciences and director of business development at Lion Bioscience.
 

Epitome Biosystems has named Edward Machuga VP of sales and marketing. Machuga previously served in sales and marketing roles at GE Healthcare, TekCel, Argonaut Technologies, Applied Biosystems, and Perseptive Biosystems.
 

Cepheid has appointed a new scientific advisory board. Members include Alex van Belkum, a professor of microbiology at Erasmus Medical Center; Carlo Croce, director of the Human Cancer Genetics Program and the Genetics Institute at Ohio State University; Herbert Fritsche, professor of laboratory medicine and chief of clinical chemistry at the University of Texas MD Anderson Cancer Center; Joe Gray, director of the life sciences division at Lawrence Berkeley National Laboratory; Patrick Murray, chief of microbiology service in the Department of Laboratory Medicine at the National Institutes of Health Clinical Center; Franklyn Prendergast, professor of molecular pharmacology and experimental therapeutics at the Mayo Clinic; David Relman, chief of infectious diseases at the Palo Alto Veteran's Administration Hospital and associate professor of medicine, microbiology, and immunology at Stanford University’s School of Medicine; and Michael Sarosdy, a urologic surgeon at the Cancer Therapy and Research Center, San Antonio.
 

Madhav Gadgil and Samir Brahmachari this week won HK Firodia 2007 awards for excellence in science and technology for their work in with the Indian Functional Genomics Initiative.
 
Brahmachari is director of the Institute of Genomics and Integrative Biology in Delhi, and Gadgil founded the country’s first biosphere reserve and founded the Center for Ecological Sciences at the Indian Institute of Science in Bangalore.
 

Promoted? Changing jobs? GenomeWeb wants to know. E-mail [email protected] to appear in PEOPLE, a weekly roundup of industry comings and goings.

The Scan

Study Finds Few FDA Post-Market Regulatory Actions Backed by Research, Public Assessments

A Yale University-led team examines in The BMJ safety signals from the US FDA Adverse Event Reporting System and whether they led to regulatory action.

Duke University Team Develops Programmable RNA Tool for Cell Editing

Researchers have developed an RNA-based editing tool that can target specific cells, as they describe in Nature.

Novel Gene Editing Approach for Treating Cystic Fibrosis

Researchers in Science Advances report on their development of a non-nuclease-based gene editing approach they hope to apply to treat cystic fibrosis.

Study Tracks Responses in Patients Pursuing Polygenic Risk Score Profiling

Using interviews, researchers in the European Journal of Human Genetics qualitatively assess individuals' motivations for, and experiences with, direct-to-consumer polygenic risk score testing.